MiNK Therapeutics (NASDAQ:INKT) Price Target Raised to $35.00 at HC Wainwright

MiNK Therapeutics (NASDAQ:INKT) had its price target hoisted by equities research analysts at HC Wainwright from $9.00 to $35.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 228.64% from the company’s previous close.

Separately, Robert W. Baird reduced their price target on shares of MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating for the company in a research report on Friday, November 15th.

MiNK Therapeutics Stock Performance

NASDAQ:INKT opened at $10.65 on Tuesday. The stock has a market capitalization of $42.17 million, a PE ratio of -2.73 and a beta of 0.17. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $19.00. The company has a fifty day moving average of $8.29 and a two-hundred day moving average of $7.71.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.